Supplementary Video 1: Human hepatocytes (THLE2) cells were incubated at 37°C for 45 mins, and then rhodamineconjugated wheat germ agglutinin (WGA) was added to cell culture for 15 mins. After washing cells with the cell culture media twice, time-lapse recording was performed for 30 mins using a Leica SP8 DMI 6000. Images shown were taken at 0, 15, and 30 min time-points. See Supplementary_Video_1
Supplementary Video 2: Human hepatocytes (THLE2) cells were incubated with 100 µg/ml trastuzumab at 37°C for 45 mins, and then rhodamine-conjugated wheat germ agglutinin (WGA) was added to cell culture for 15 mins. After washing cells with the cell culture media twice, time-lapse recording was performed for 30 mins using a Leica SP8 DMI 6000. Images shown were taken at 0, 15, and 30 min time-points. See Supplementary_Video_2
Supplementary Video 3: Human hepatocytes (THLE2) cells were incubated with 100 µg/ml brentuximab vedotin at 37°C for 45 mins, and then rhodamine-conjugated wheat germ agglutinin (WGA) was added to cell culture for 15 mins. After washing cells with the cell culture media twice, time-lapse recording was performed for 30 mins using a Leica SP8 DMI 6000.
Images shown were taken at 0, 15, and 30 min time-points. See Supplementary_Video_3
Supplementary Video 4: Human hepatocytes (THLE2) cells were incubated with 100 µg/ml T-DM1 at 37°C for 45 mins, and then rhodamine-conjugated wheat germ agglutinin (WGA) was added to cell culture for 15 mins. After washing cells with the cell culture media twice, time-lapse recording was performed for 30 mins using a Leica SP8 DMI 6000. Images shown were taken at 0, 15, and 30 min time-points. See Supplementary_Video_4
Supplementary Video 5: Human hepatocytes (THLE2) cells were incubated with 100 µg/ml α-CD22-DM1 at 37°C for 45 mins, and then rhodamine-conjugated wheat germ agglutinin (WGA) was added to cell culture for 15 mins. After washing cells with the cell culture media twice, time-lapse recording was performed for 30 mins using a Leica SP8 DMI 6000. Images shown were taken at 0, 15, and 30 min time-points. See Supplementary_Video_5 from the left. (C) Subcellular fractionation of THLE2 cells shows that caveolin-1 is found in both organelle and plasma membrane, but β1 integrin is found only in plasma membrane. (D) Knocking-down efficiency of CKAP5 protein expression by either control or CKAP5 siRNA in CHO-K1 cells. (E) Flow cytometric histogram shows that CKAP5 protein expression is detected on the cell surface of CHO-K1 cells. The cells, which CKAP5 expression is silenced by siRNA, have a decreased signal intensity as compared with that of control cells. (F and G) Flow cytometric histogram shows that α-tubulin protein is not detected on the cell surface of THLE2 cells (F) or CHO-K1 cells (G). (H) Western blot shows that CKAP5 expression in THLE2 cells is higher than that in human cardiomyocytes (HCM). (I) Flow cytometry histogram shows that CKAP5 protein expression on the cell surface of THLE2 cells is higher than that in HCM cells. (J) T-DM1 binds to CKAP5 from the plasma membrane fraction of CHO-K1 cells. After incubating 250 µg/ml trastuzumab and T-DM1 with CHO-K1 cells in HBSS at RT for 1 hour, cell surface proteins were cross-linked by DTSSP, and the WCLs were subjected to subcellular fractionation into cytosol and plasma membrane (PM) fraction. PM fraction was solubilized and then subjected to immunoprecipitation. (K) Anti-CKAP5 antibody blocks the binding of T-DM1 to the THLE2 cells. Amounts of cell-bound T-DM1 are examined in WCL of THLE2 cells which were pre-incubated with 10 µg/ml rabbit IgG, anti-CKAP5 Ab1 (cat# HPA039377, Sigma-Aldrich), or anti-CKAP5 (cat# HPA040375, Sigma-Aldrich) at 37°C for 1 hour, and cells then were incubated with 100 µg/ml T-DM1 at 37°C for 1 hour. The amount of cell-bound T-DM1 was reduced in the cells pre-treated with anti-CKAP5, compared to that in the cells pre-treated with control IgG or anti-CKAP5 Ab1 antibody.
